Healthcare -
Biotechnology - NASDAQ - US
$ 0.493
1.46 %
$ 28.6 M
Market Cap
-0.29
P/E
Price Target
Average
914.20%
Revenue Forecast
Estimate
-0.00%
EBIT
Estimate
50.65%
Net Income
Estimate
22.35%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
BioAtla, Inc.
Wall Street analysts predict an average 1-year price target for BCAB of $5 , with forecasts ranging from
a
low of
$5 to a high of $5 .
BCAB Lowest Price Target
Wall Street Target
5 USD
914.20%
BCAB Average Price Target
Wall Street Target
5 USD
914.20%
BCAB Highest Price Target
Wall Street Target
5 USD
914.20%
REVENUE FORECAST
Revenue Forecast Chart BCAB
EBIT FORECAST
EBIT Forecast Chart BCAB
NET INCOME FORECAST
Net Income Chart BCAB